Showing results (231-240 of 969) with videos related to

Sort By:
Pageof 97
Leukemia & Lymphoma|October 10, 2009
Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategyDeborah A Thomas, Farhad Ravandi, Michael Keating, et al.
Expert Review of Hematology|November 25, 2010
Acute erythroleukemia: diagnosis and managementFabio P S Santos, Carlos E Bueso-Ramos, Farhad Ravandi
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2013
Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemiaKumudha Balakrishnan, Farhad Ravandi, Shanta Bantia, et al.
Cancer|December 31, 2015
The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapyLorenzo Falchi, Srdan Verstovsek, Farhad Ravandi-Kashani, et al.
Blood Advances|December 22, 2020
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AMLNicholas J Short, Hind Rafei, Naval Daver, et al.
Cancer|April 9, 2024
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemiaElias Jabbour, Fadi G Haddad, Koji Sasaki, et al.
Blood Cancer Journal|May 6, 2020
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotypeBachar Samra, Guillaume Richard-Carpentier, Tapan M Kadia, et al.
The Lancet. Haematology|December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Cancer|April 7, 2025
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trialHannah Goulart, Hagop Kantarjian, Gautam Borthakur, et al.
Hemasphere|October 24, 2025
A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemiaWei-Ying Jen, Jennifer Croden, Emmanuel Almanza-Huante, et al.
Pageof 97